Compare Crown Castle International Corp (CCI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs Mesoblast Limited — how do they compare? Crown Castle International Corp trades at $79.21 (market cap $34.50B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Crown Castle International Corp is far larger — about 16.3× Mesoblast Limited's market cap, and Crown Castle International Corp pays a 5.38% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| CCI | MESO | |
|---|---|---|
Market Cap | $34.50B | $2.12B |
Sector | Real Estate | Technology |
52-Week High | $113.91 | $20.96 |
52-Week Low | $74.92 | $10.96 |
Enterprise Value | $64.33B | $2.13B |
Dividend Yield | 5.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $79.84, up 0.23% on the day, with a bearish technical signal from moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, but maintains strong profitability with a 73.82% gross margin. Recent news highlights its pure-play U.S. tower focus and upcoming Q2 2026 earnings call on July 22, 2026.
CCI presents a turnaround opportunity with analyst consensus targeting $97.33, implying 22% upside, but faces risks from high debt levels and volatile earnings. The stock's negative equity and bearish technicals warrant caution despite attractive dividend yield and cost reduction initiatives.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
